Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein C
Authors:
- Bas de LaatBLBas de Laat
- Carel M EckmannCECarel M Eckmann
- Marlies van SchagenMSMarlies van Schagen
- Alexander B MeijerAMAlexander B Meijer
- Koen MertensKMKoen Mertens
- Jan A van MourikJMJan A van Mourik
- 1 December 2008
- journal article
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 19 (8) , 757-764
Abstract
The antiphospholipid syndrome is characterized by the occurrence of vascular thrombosis combined with the presence of antiphospholipid antibodies in plasma of patients. It has been published that antibeta2-glycoprotein I (beta2-GPI) antibodies, with lupus anticoagulant activity (LAC), highly correlate with thrombosis. Resistance related to antiphospholipid antibodies against activated protein C (APC) is one of the proposed mechanisms responsible for thrombosis. We investigated a possible correlation between a beta2-GPI-dependent LAC (titration of cardiolipin into an activated partial thromboplastin time-based assay) and increased APC resistance in a population of 22 plasma samples with LAC activity. Eleven plasma samples that displayed a beta2-GPI-dependent LAC also showed increased APC resistance. In contrast, only one of the 11 plasma samples with a beta2-GPI-independent LAC displayed increased APC resistance. In addition, a monoclonal antibeta2-GPI antibody and patient-purified immunoglobulin G (both with LAC activity) were diluted in plasma with/without protein C. Both antibodies only displayed a beta2-GPI-dependent LAC in plasma in the presence of protein C. This indicates that the principle of the beta2-GPI LAC-assay was based on increased resistance against protein C. Surface plasmon resonance analysis was used to investigate binding between APC and beta2-GPI. We observed that beta2-GPI was able to bind APC directly, especially in the presence of a monoclonal antibeta2-GPI antibody. In conclusion, our observations show a direct correlation between a major clinical symptom of antiphospholipid syndrome (thrombosis), a diagnostic assay (beta2-GPI-dependent LAC) and a potential mechanism responsible for thrombosis in the antiphospholipid syndrome (increased APC resistance).Keywords
This publication has 21 references indexed in Scilit:
- Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66 155 cases and 91 307 controlsThe Lancet, 2006
- Inhibition of APC anticoagulant activity on oxidized phospholipid by anti–β2-glycoprotein I monoclonal antibodiesBlood, 2005
- Anti‐β2‐glycoprotein I antibody testing in the laboratory diagnosis of antiphospholipid syndromeJournal of Thrombosis and Haemostasis, 2005
- Research around β2-glycoprotein I: A major target for antiphospholipid antibodiesAutoimmunity, 2005
- β2-glycoprotein I–dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndromeBlood, 2004
- A simple method to discriminate between β2-glycoprotein I- and prothrombin-dependent lupus anticoagulantsJournal of Thrombosis and Haemostasis, 2003
- Differential Effects of Anti–β2-Glycoprotein I and Antiprothrombin Antibodies on the Anticoagulant Activity of Activated Protein CBlood, 1998
- Laboratory Identification of Lupus Anticoagulants: Results of the Second International Workshop for Identification of Lupus AnticoagulantsThrombosis and Haemostasis, 1995
- Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutationThe Lancet, 1994
- Thrombosis, abortion, cerebral disease, and the lupus anticoagulant.BMJ, 1983